Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AKBETA vs BYSTOLIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AKBETA is not a recognized drug; please verify the drug name.
Bystolic (nebivolol) is a beta-1 selective adrenergic receptor antagonist with additional nitric oxide-mediated vasodilatory effects. It decreases heart rate, myocardial contractility, and blood pressure by blocking beta-1 receptors in the heart and kidney, and enhances nitric oxide release from vascular endothelium via beta-3 receptor activation.
No verified indications
Hypertension: treatment of hypertension, alone or in combination with other antihypertensives,Heart failure: stable mild to moderate chronic heart failure in addition to standard therapy (off-label)
Metoprolol tartrate: 50-100 mg orally twice daily; metoprolol succinate: 25-200 mg orally once daily.
Oral: 5 mg once daily; may increase at 2-week intervals to 10 mg, 20 mg, 40 mg; maximum 40 mg/day.
Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged to 10-20 hours in severe renal impairment.
Terminal elimination half-life: 10-12 hours; allows once-daily dosing in most patients; steady-state achieved in 3-5 days
Unknown
Extensively metabolized via CYP2D6 and glucuronidation. Active metabolites are formed, including desmethylnebivolol. Genetic polymorphisms in CYP2D6 affect drug levels.
Renal excretion accounts for 80-85% of the dose, primarily as unchanged drug; biliary/fecal elimination is 10-15%.
Renal: 38% unchanged; hepatic metabolism: extensive; fecal: minor; total renal clearance accounts for 30-50% of dose
60-70% bound primarily to albumin and alpha-1-acid glycoprotein.
25-30% bound to albumin (alpha-1-acid glycoprotein not significant)
Vd is 1.0-2.0 L/kg, indicating extensive tissue distribution.
Vd: ~2.5 L/kg (extensive extravascular distribution, consistent with moderate lipophilicity)
Oral: 50-60% due to first-pass hepatic metabolism; IV: 100%.
Oral: 33% (due to first-pass metabolism; food does not significantly affect AUC; low variability)
No dose adjustment required for mild to moderate renal impairment; in severe renal impairment (GFR < 10 m L/min), administer with caution.
No adjustment for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), initial dose 2.5 mg once daily; titrate cautiously; maximum 20 mg/day.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh Class A: initial 2.5 mg once daily; increase cautiously; maximum 20 mg/day. Child-Pugh Class B: initial 2.5 mg once daily; increase cautiously; maximum 10 mg/day. Child-Pugh Class C: not recommended.
1-2 mg/kg per day orally in divided doses; maximum 200 mg/day.
Not established; safety and efficacy not evaluated in pediatric patients.
Initiate at lower end of dosing range (e.g., 25 mg once daily for metoprolol succinate), titrate slowly due to increased risk of bradycardia and hypotension.
Initial dose 2.5 mg once daily; titrate slowly; maximum 40 mg/day. Monitor heart rate and blood pressure closely.
No boxed warning applicable
No FDA black box warning.
No warnings due to lack of data
Abrupt discontinuation may exacerbate angina or myocardial infarction in coronary artery disease,May mask signs of hyperthyroidism,Caution in peripheral vascular disease and Raynaud's phenomenon,May cause bronchospasm in patients with asthma or COPD,Caution in patients with diabetes mellitus due to masking of hypoglycemia,May cause bradycardia or heart block,Caution in renal or hepatic impairment
No contraindications identified
Sinus bradycardia,Second- or third-degree heart block,Cardiogenic shock,Decompensated heart failure,Sick sinus syndrome (unless pacemaker present),Severe hepatic impairment,Hypersensitivity to nebivolol or any component
No significant food interactions. Taking with meals may reduce gastrointestinal irritation. Avoid excessive salt intake as it may exacerbate Meniere's symptoms.
Avoid alcohol as it may increase blood pressure-lowering effect. No significant food interactions; however, grapefruit juice may slightly increase nebivolol levels but not clinically relevant.
Pregnancy category D. First trimester: Associated with fetal bradycardia, hypoglycemia, and growth restriction; beta-blocker exposure increases risk of low birth weight. Second trimester: Continued risk of fetal bradycardia and growth restriction; may cause placental hypoperfusion. Third trimester: Risk of neonatal hypoglycemia, bradycardia, and respiratory depression; beta-blockade may attenuate fetal heart rate response to distress.
First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Beta-blockers may cause fetal bradycardia, intrauterine growth restriction, and neonatal hypoglycemia; risk is dose-dependent.
Atenolol is excreted in breast milk with a high M/P ratio of approximately 4.6. Peak milk levels occur 2-4 hours after dose. Due to potential for infant bradycardia and hypoglycemia, use is not recommended; if used, monitor infant for signs of beta-blockade.
Nebivolol is excreted into breast milk; M/P ratio not established. Limited human data; use with caution in nursing mothers due to potential for infant bradycardia and hypotension.
Atenolol is not recommended in pregnancy due to fetotoxicity; use alternative beta-blocker with better safety profile (e.g., labetalol). If used, dose requirements may increase due to expanded plasma volume and increased renal clearance; dose should be individualized based on maternal heart rate and blood pressure response.
No specific dose adjustments established; use lowest effective dose; increase monitoring for maternal hypotension and fetal bradycardia; consider discontinuation if fetal distress occurs.
AKBETA (betahistine) is primarily used for Meniere's disease. Titrate dose gradually to minimize GI upset. Avoid in patients with pheochromocytoma or severe asthma. Monitor for hypotension and bradycardia. Efficacy may take weeks to manifest.
Bystolic (nebivolol) is a beta-1 selective blocker with nitric oxide-mediated vasodilation, resulting in lower incidence of fatigue and sexual dysfunction compared to other beta-blockers. No dose adjustment needed in mild to moderate hepatic impairment but contraindicated in severe impairment. Maximum antihypertensive effect may take 2 weeks. Use caution in patients with asthma or COPD due to beta-1 selectivity may be lost at higher doses. Do not discontinue abruptly; taper over 1-2 weeks.
Take with or after meals to reduce stomach upset.,Do not drive or operate machinery if you experience dizziness or drowsiness.,Report any worsening of asthma symptoms or irregular heartbeat.,Avoid alcohol as it may increase side effects like dizziness.,Store at room temperature away from moisture and heat.
Take once daily at the same time each day, with or without food.,Do not stop taking suddenly as this may cause chest pain or heart attack; consult your doctor for gradual dose reduction.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how you react.,Notify your doctor if you experience slow heartbeat, shortness of breath, swelling of feet or legs, or signs of allergic reaction.,Inform all healthcare providers that you take this medication, especially before surgery or any procedure involving anesthesia.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AKBETA vs BYSTOLIC, answered by our medical review team.
AKBETA is a Beta Blocker (Ophthalmic) that works by AKBETA is not a recognized drug; please verify the drug name.. BYSTOLIC is a Beta Blocker that works by Bystolic (nebivolol) is a beta-1 selective adrenergic receptor antagonist with additional nitric oxide-mediated vasodilatory effects. It decreases heart rate, myocardial contractility, and blood pressure by blocking beta-1 receptors in the heart and kidney, and enhances nitric oxide release from vascular endothelium via beta-3 receptor activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AKBETA and BYSTOLIC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AKBETA is: Metoprolol tartrate: 50-100 mg orally twice daily; metoprolol succinate: 25-200 mg orally once daily.. The standard adult dose of BYSTOLIC is: Oral: 5 mg once daily; may increase at 2-week intervals to 10 mg, 20 mg, 40 mg; maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AKBETA and BYSTOLIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AKBETA is classified as Category C. Pregnancy category D. First trimester: Associated with fetal bradycardia, hypoglycemia, and growth restriction; beta-blocker exposure increases risk of low birth weight. Second tri. BYSTOLIC is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Beta-blockers may cause fetal bradycardia, intraute. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.